Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
189.22B
Market cap189.22B
Price-Earnings ratio
24.70
Price-Earnings ratio24.70
Dividend yield
2.76%
Dividend yield2.76%
Average volume
2.87M
Average volume2.87M
High today
$358.30
High today$358.30
Low today
$349.56
Low today$349.56
Open price
$355.28
Open price$355.28
Volume
4.30M
Volume4.30M
52 Week high
$391.29
52 Week high$391.29
52 Week low
$267.83
52 Week low$267.83

Stock Snapshot

With a market cap of 189.22B, Amgen(AMGN) trades at $352.50. The stock has a price-to-earnings ratio of 24.70 and currently yields dividends of 2.8%.

On 2026-06-15, Amgen(AMGN) stock moved within a range of $349.56 to $358.30. With shares now at $352.50, the stock is trading +0.8% above its intraday low and -1.6% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 4.3M, versus its average volume of 2.87M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $267.83.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $267.83.

AMGN News

Nasdaq 12h
Amgen Reaches Analyst Target Price

In recent trading, shares of Amgen Inc (Symbol: AMGN) have crossed above the average analyst 12-month target price of $242.67, changing hands for $243.12/share....

Amgen Reaches Analyst Target Price
TipRanks 22h
HBM Wins U.S. Jury Verdict in Patent Fight Over Antibody Discovery Platform

HBM Holdings Ltd. ( (HK:2142) ) has issued an announcement. HBM Holdings Limited has secured a significant legal victory in the United States, where a Delaware...

Simply Wall St 2d
Amgen Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st

...

Amgen Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st

Analyst ratings

47%

of 36 ratings
Buy
41.7%
Hold
47.2%
Sell
11.1%

More AMGN News

CNBC 2d
Drugmakers race to find a place in the next wave of obesity drugs

Key Points Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors...

Benzinga 3d
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal

The company argues that the drug's benefits continue to outweigh its risks for patients with a rare autoimmune disease. The request, submitted by Amgen and its...

Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal
Nasdaq 5d
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

Amgen AMGN is one of the several drug makers racing to develop an innovative weight-loss drug and take a share of the booming weight loss drug market. The globa...

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
TipRanks 5d
Amgen price target raised to $340 from $332 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $340 from $332 and keeps an Equal Weight rating on the shares. The firm,...

Nasdaq 6d
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products...

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.